{"id":81490,"date":"2026-06-06T00:05:09","date_gmt":"2026-06-06T00:05:09","guid":{"rendered":"https:\/\/english.saigonbiz.com\/vn\/oban-biopharma-announces-presentation-of-late-breaking-abstract-at-ada-2026-highlighting-obt-676-a-first-in-class-small-molecule-combining-dual-amylin-and-calcitonin-receptor-full-agonism-dacra-wit\/"},"modified":"2026-06-06T00:05:09","modified_gmt":"2026-06-06T00:05:09","slug":"oban-biopharma-announces-presentation-of-late-breaking-abstract-at-ada-2026-highlighting-obt-676-a-first-in-class-small-molecule-combining-dual-amylin-and-calcitonin-receptor-full-agonism-dacra-wit","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/oban-biopharma-announces-presentation-of-late-breaking-abstract-at-ada-2026-highlighting-obt-676-a-first-in-class-small-molecule-combining-dual-amylin-and-calcitonin-receptor-full-agonism-dacra-wit\/","title":{"rendered":"Oban BioPharma Announces Presentation of Late-Breaking Abstract at ADA 2026 Highlighting OBT-676: A First-in-Class Small Molecule Combining Dual Amylin and Calcitonin Receptor Full Agonism (DACRA) with GLP-1, GIP and Glucagon (Triple-G) Receptor Partial Agonism"},"content":{"rendered":"<div>\n<p align=\"justify\">STAMFORD, Conn., June  05, 2026  (GLOBE NEWSWIRE) &#8212; Oban BioPharma today announced that preclinical data for\u00a0<strong>OBT-676<\/strong>, a lead small-molecule candidate for the treatment of obesity and type 2 diabetes, has been selected for a late-breaking presentation at the upcoming American Diabetes Association (ADA) 86th Scientific Sessions being held from June 5<sup>th<\/sup>-8<sup>th<\/sup> in New Orleans, LA. The study characterizes OBT-676 as a new molecular entity that achieves potent full agonism at the amylin and calcitonin receptors (DACRA) while simultaneously delivering partial agonism across the GLP-1, GIP, and glucagon (Triple-G) pathways. OBT-676 demonstrated significant reduction in food intake and adipose-selective weight loss in the industry-standard rat diet-induced obesity (DIO) model.<\/p>\n<p align=\"justify\">&#8220;The OBT-676 data being presented at ADA underscores a significant leap in the evolution of small molecule, multimodal metabolic therapies\u201d, said Derek Chalmers, Ph.D., D.Sc., Co-Founder &amp; CEO of Oban BioPharma. \u201cWith OBT-676, and a series of related analogs, we have moved beyond incretin receptor-focused injectable peptides to an oral small molecule class targeting multiple metabolic systems, encompassing potent amylin receptor activation paired with balanced incretin and glucagon receptor signaling. These DACRA\/Triple-G small molecule compounds have the potential of shifting the treatment goal for millions of patients managing chronic metabolic diseases from simple weight reduction to high-quality metabolic restoration, prioritizing adipose-biased weight loss and superior tolerability with an orally available drug.\u201d<\/p>\n<p align=\"justify\"><strong>Presentation Details:<\/strong><\/p>\n<p align=\"justify\"><strong>Title:<\/strong> OBT-676, a Novel Oral Small Molecule Combining Full DACRA Activity with \u201cTriple-G\u201d Partial Agonism for the Treatment of Metabolic Diseases<br \/><strong>Poster #:<\/strong> LB-2848<br \/><strong>Session:<\/strong> Late Breaking<br \/><strong>Date:<\/strong> Sunday June 8<sup>th<br \/><\/sup><strong>Time:<\/strong> 12.30pm-1.30pm CT<br \/><strong>Summary<\/strong>: OBT-676 exhibited picomolar potency and full agonism at AMY-1, AMY-3, and calcitonin receptors along with calibrated partial agonism at GLP-1, GIP and Glucagon receptors. Administration of OBT-676 in diet-induced obese rats resulted in significant, dose-dependent reductions in food intake and adipose-selective weight loss.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zQCjMdBZ-Y6HCch9xQq8k5i0rjoW0NH6rjZbGQ7JIvXnl0bT2NPPLwOBzNiUm4h7kzQA_3haMXK9TIjAcwyQFAXRTvpwKr-p3ATRnrgUNjcVVWctQ3CufFxj11jZXXCppGlF8kGu_t_E3DMgxcmFIFldZwun-sey_lMTTgv1YoDPwJvWQvGetxSwpqAJCEYbtfyDXnbgXaMM9fca0sJMBJGJsT2jxXbD9AavgkJslfkrQPgoXoHqsyb0oE7_GzHd_T0xbw0J5RSMBTkBLr-alg==\" rel=\"nofollow\" target=\"_blank\" title=\"2848-LP ADA Poster Final 29May26 QR.pdf\">2848-LP ADA Poster Final 29May26 QR.pdf<\/a><\/p>\n<p align=\"justify\"><strong>About Oban BioPharma<\/strong><\/p>\n<p align=\"justify\">Oban BioPharma is a privately held biotechnology company focused on the development of novel oral small molecule GPCR-targeted therapeutics for metabolic and CNS diseases. Oban combines the power of computational structural and chemotype analysis with AI-based \u201cdruggability\u201d filters to create a faster, more efficient path to new medicines.<\/p>\n<p align=\"justify\">For additional information please visit: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LSYbUlsyHgQJTnFcsbIyEISSSSCx3bOKwa9Llohrk6rDQzPJZ2liaB3mF8Qi9v0z2jbztFk3R-CAORIJle9t1AntQZZZDc2ro-F5j_1Blnk=\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/obanbiopharma.com<\/a><\/p>\n<p align=\"justify\">Contact: info@obanbiopharma.com<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZWM3YTU3NGYtZGExMy00YTlhLWE4NTQtYjUwNWU1ZmY3ZjdlLTEzMjI5MjItMjAyNi0wNi0wNS1lbg==\/tiny\/Oban-BioPharma-Inc-.png\" referrerpolicy=\"no-referrer-when-downgrade\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>STAMFORD, Conn., June 05, 2026 (GLOBE NEWSWIRE) &#8212; Oban BioPharma today announced that preclinical data for\u00a0OBT-676, a lead small-molecule candidate for the treatment of obesity and type 2 diabetes, has been selected for a late-breaking presentation at the upcoming American Diabetes Association (ADA) 86th Scientific Sessions being held from June 5th-8th in New Orleans, LA. [&#8230;]\n","protected":false},"author":1,"featured_media":85254,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"class_list":["post-81490","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-people"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Oban BioPharma Announces Presentation of Late-Breaking Abstract at ADA 2026 Highlighting OBT-676: A First-in-Class Small Molecule Combining Dual Amylin and Calcitonin Receptor Full Agonism (DACRA) with GLP-1, GIP and Glucagon (Triple-G) Receptor Partial Agonism - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/oban-biopharma-announces-presentation-of-late-breaking-abstract-at-ada-2026-highlighting-obt-676-a-first-in-class-small-molecule-combining-dual-amylin-and-calcitonin-receptor-full-agonism-dacra-wit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Oban BioPharma Announces Presentation of Late-Breaking Abstract at ADA 2026 Highlighting OBT-676: A First-in-Class Small Molecule Combining Dual Amylin and Calcitonin Receptor Full Agonism (DACRA) with GLP-1, GIP and Glucagon (Triple-G) Receptor Partial Agonism\" \/>\n<meta property=\"og:description\" content=\"STAMFORD, Conn., June 05, 2026 (GLOBE NEWSWIRE) &#8212; Oban BioPharma today announced that preclinical data for\u00a0OBT-676, a lead small-molecule candi\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/oban-biopharma-announces-presentation-of-late-breaking-abstract-at-ada-2026-highlighting-obt-676-a-first-in-class-small-molecule-combining-dual-amylin-and-calcitonin-receptor-full-agonism-dacra-wit\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-06T00:05:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/05\/SaigonBiz-Feature-Image.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1074\" \/>\n\t<meta property=\"og:image:height\" content=\"716\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/oban-biopharma-announces-presentation-of-late-breaking-abstract-at-ada-2026-highlighting-obt-676-a-first-in-class-small-molecule-combining-dual-amylin-and-calcitonin-receptor-full-agonism-dacra-wit\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/oban-biopharma-announces-presentation-of-late-breaking-abstract-at-ada-2026-highlighting-obt-676-a-first-in-class-small-molecule-combining-dual-amylin-and-calcitonin-receptor-full-agonism-dacra-wit\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Oban BioPharma Announces Presentation of Late-Breaking Abstract at ADA 2026 Highlighting OBT-676: A First-in-Class Small Molecule Combining Dual Amylin and Calcitonin Receptor Full Agonism (DACRA) with GLP-1, GIP and Glucagon (Triple-G) Receptor Partial Agonism\",\"datePublished\":\"2026-06-06T00:05:09+00:00\",\"dateModified\":\"2026-06-06T00:05:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/oban-biopharma-announces-presentation-of-late-breaking-abstract-at-ada-2026-highlighting-obt-676-a-first-in-class-small-molecule-combining-dual-amylin-and-calcitonin-receptor-full-agonism-dacra-wit\/\"},\"wordCount\":404,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"People\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/oban-biopharma-announces-presentation-of-late-breaking-abstract-at-ada-2026-highlighting-obt-676-a-first-in-class-small-molecule-combining-dual-amylin-and-calcitonin-receptor-full-agonism-dacra-wit\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/oban-biopharma-announces-presentation-of-late-breaking-abstract-at-ada-2026-highlighting-obt-676-a-first-in-class-small-molecule-combining-dual-amylin-and-calcitonin-receptor-full-agonism-dacra-wit\/\",\"name\":\"Oban BioPharma Announces Presentation of Late-Breaking Abstract at ADA 2026 Highlighting OBT-676: A First-in-Class Small Molecule Combining Dual Amylin and Calcitonin Receptor Full Agonism (DACRA) with GLP-1, GIP and Glucagon (Triple-G) Receptor Partial Agonism - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2026-06-06T00:05:09+00:00\",\"dateModified\":\"2026-06-06T00:05:09+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/oban-biopharma-announces-presentation-of-late-breaking-abstract-at-ada-2026-highlighting-obt-676-a-first-in-class-small-molecule-combining-dual-amylin-and-calcitonin-receptor-full-agonism-dacra-wit\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/oban-biopharma-announces-presentation-of-late-breaking-abstract-at-ada-2026-highlighting-obt-676-a-first-in-class-small-molecule-combining-dual-amylin-and-calcitonin-receptor-full-agonism-dacra-wit\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/oban-biopharma-announces-presentation-of-late-breaking-abstract-at-ada-2026-highlighting-obt-676-a-first-in-class-small-molecule-combining-dual-amylin-and-calcitonin-receptor-full-agonism-dacra-wit\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Oban BioPharma Announces Presentation of Late-Breaking Abstract at ADA 2026 Highlighting OBT-676: A First-in-Class Small Molecule Combining Dual Amylin and Calcitonin Receptor Full Agonism (DACRA) with GLP-1, GIP and Glucagon (Triple-G) Receptor Partial Agonism\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Oban BioPharma Announces Presentation of Late-Breaking Abstract at ADA 2026 Highlighting OBT-676: A First-in-Class Small Molecule Combining Dual Amylin and Calcitonin Receptor Full Agonism (DACRA) with GLP-1, GIP and Glucagon (Triple-G) Receptor Partial Agonism - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/oban-biopharma-announces-presentation-of-late-breaking-abstract-at-ada-2026-highlighting-obt-676-a-first-in-class-small-molecule-combining-dual-amylin-and-calcitonin-receptor-full-agonism-dacra-wit\/","og_locale":"en_US","og_type":"article","og_title":"Oban BioPharma Announces Presentation of Late-Breaking Abstract at ADA 2026 Highlighting OBT-676: A First-in-Class Small Molecule Combining Dual Amylin and Calcitonin Receptor Full Agonism (DACRA) with GLP-1, GIP and Glucagon (Triple-G) Receptor Partial Agonism","og_description":"STAMFORD, Conn., June 05, 2026 (GLOBE NEWSWIRE) &#8212; Oban BioPharma today announced that preclinical data for\u00a0OBT-676, a lead small-molecule candi","og_url":"https:\/\/english.saigonbiz.com\/vn\/oban-biopharma-announces-presentation-of-late-breaking-abstract-at-ada-2026-highlighting-obt-676-a-first-in-class-small-molecule-combining-dual-amylin-and-calcitonin-receptor-full-agonism-dacra-wit\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2026-06-06T00:05:09+00:00","og_image":[{"width":1074,"height":716,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/05\/SaigonBiz-Feature-Image.jpg","type":"image\/jpeg"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/oban-biopharma-announces-presentation-of-late-breaking-abstract-at-ada-2026-highlighting-obt-676-a-first-in-class-small-molecule-combining-dual-amylin-and-calcitonin-receptor-full-agonism-dacra-wit\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/oban-biopharma-announces-presentation-of-late-breaking-abstract-at-ada-2026-highlighting-obt-676-a-first-in-class-small-molecule-combining-dual-amylin-and-calcitonin-receptor-full-agonism-dacra-wit\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Oban BioPharma Announces Presentation of Late-Breaking Abstract at ADA 2026 Highlighting OBT-676: A First-in-Class Small Molecule Combining Dual Amylin and Calcitonin Receptor Full Agonism (DACRA) with GLP-1, GIP and Glucagon (Triple-G) Receptor Partial Agonism","datePublished":"2026-06-06T00:05:09+00:00","dateModified":"2026-06-06T00:05:09+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/oban-biopharma-announces-presentation-of-late-breaking-abstract-at-ada-2026-highlighting-obt-676-a-first-in-class-small-molecule-combining-dual-amylin-and-calcitonin-receptor-full-agonism-dacra-wit\/"},"wordCount":404,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["People"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/oban-biopharma-announces-presentation-of-late-breaking-abstract-at-ada-2026-highlighting-obt-676-a-first-in-class-small-molecule-combining-dual-amylin-and-calcitonin-receptor-full-agonism-dacra-wit\/","url":"https:\/\/english.saigonbiz.com\/vn\/oban-biopharma-announces-presentation-of-late-breaking-abstract-at-ada-2026-highlighting-obt-676-a-first-in-class-small-molecule-combining-dual-amylin-and-calcitonin-receptor-full-agonism-dacra-wit\/","name":"Oban BioPharma Announces Presentation of Late-Breaking Abstract at ADA 2026 Highlighting OBT-676: A First-in-Class Small Molecule Combining Dual Amylin and Calcitonin Receptor Full Agonism (DACRA) with GLP-1, GIP and Glucagon (Triple-G) Receptor Partial Agonism - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2026-06-06T00:05:09+00:00","dateModified":"2026-06-06T00:05:09+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/oban-biopharma-announces-presentation-of-late-breaking-abstract-at-ada-2026-highlighting-obt-676-a-first-in-class-small-molecule-combining-dual-amylin-and-calcitonin-receptor-full-agonism-dacra-wit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/oban-biopharma-announces-presentation-of-late-breaking-abstract-at-ada-2026-highlighting-obt-676-a-first-in-class-small-molecule-combining-dual-amylin-and-calcitonin-receptor-full-agonism-dacra-wit\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/oban-biopharma-announces-presentation-of-late-breaking-abstract-at-ada-2026-highlighting-obt-676-a-first-in-class-small-molecule-combining-dual-amylin-and-calcitonin-receptor-full-agonism-dacra-wit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Oban BioPharma Announces Presentation of Late-Breaking Abstract at ADA 2026 Highlighting OBT-676: A First-in-Class Small Molecule Combining Dual Amylin and Calcitonin Receptor Full Agonism (DACRA) with GLP-1, GIP and Glucagon (Triple-G) Receptor Partial Agonism"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/81490","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=81490"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/81490\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/85254"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=81490"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=81490"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=81490"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}